0001171843-22-007635.txt : 20221122 0001171843-22-007635.hdr.sgml : 20221122 20221122161549 ACCESSION NUMBER: 0001171843-22-007635 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221118 FILED AS OF DATE: 20221122 DATE AS OF CHANGE: 20221122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bisker-Leib Vered CENTRAL INDEX KEY: 0001814093 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39696 FILM NUMBER: 221410552 MAIL ADDRESS: STREET 1: C/O COMPASS STREET 2: 245 FIRST STREET, 3RD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Compass Therapeutics, Inc. CENTRAL INDEX KEY: 0001738021 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-500-8099 MAIL ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: Olivia Ventures, Inc. DATE OF NAME CHANGE: 20180419 4 1 ownership.xml X0306 4 2022-11-18 0 0001738021 Compass Therapeutics, Inc. CMPX 0001814093 Bisker-Leib Vered C/O COMPASS THERAPEUTICS, INC. 80 GUEST ST., SUITE 601 BOSTON MA 02135 0 1 0 0 Chief Operating Officer Common Stock 2022-11-18 4 S 0 6226 4.40 D 1107175 D Common Stock 2022-11-21 4 S 0 16035 4.34 D 1084914 D The sales reported on this Form represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are included in the Reporting Person's award agreement which allows the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction. The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.31 to $4.49 per share on November 18, 2022 and $4.30 to $4.44 on November 21, 2022. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above. /s/ Vered Bisker-Leib 2022-11-22